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Cellular Intrinsic Factors Involved in the Resistance of
Squamous Cell Carcinoma to Photodynamic Therapy
Yolanda Gilaberte1, Laura Milla2, Nerea Salazar3, Jesu´s Vera-Alvarez4, Omar Kourani3, Alejandra Damian3,
Viviana Rivarola2, Maria Jose´ Roca4, Jesu´s Espada3, Salvador Gonza´lez5,6 and Angeles Juarranz3,6
Photodynamic therapy (PDT) is widely used to treat non-melanoma skin cancer. However, some patients affected
with squamous cell carcinoma (SCC) do not respond adequately to PDT with methyl-d-aminolevulinic acid (MAL-
PDT) and the tumors acquire an infiltrative phenotype and became histologically more aggressive, less
differentiated, and more fibroblastic. To search for potential factors implicated in SCC resistance to PDT, we
have used the SCC-13 cell line (parental) and resistant SCC-13 cells obtained by repeated MAL-PDT treatments
(5th and 10th PDT-resistant generations). Xenografts assays in immunodeficient mice showed that the tumors
generated by resistant cells were bigger than those induced by parental cells. Comparative genomic hybridization
array (aCGH) showed that the three cell types presented amplicons in 3p12.1 CADM2, 7p11.2 EFGR, and 11q13.3
CCND1 genes. The 5th and 10th PDT-resistant cells showed an amplicon in 5q11.2 MAP3K1, which was not present
in parental cells. The changes detected by aCGH on CCND1, EFGR, and MAP3K1 were confirmed in extracts of
SCC-13 cells by reverse-transcriptase PCR and by western blot, and by immunohistochemistry in human biopsies
from persistent tumors after MAL-PDT. Our data suggest that genomic imbalances related to CCND1, EFGR, and
particularly MAP3K1 seem to be involved in the development of the resistance of SCC to PDT.
Journal of Investigative Dermatology (2014) 134, 2428–2437; doi:10.1038/jid.2014.178; published online 15 May 2014
INTRODUCTION
Non-melanoma skin cancer (NMSC) is the most common
malignancy occurring in the White population (Neville et al.,
2007; Lomas et al., 2012). NMSC basically comprises basal
cell carcinoma and squamous cell carcinoma (SCC).
Photodynamic therapy (PDT) has been revealed as an
excellent treatment for NMSC. PDT consists in the
administration of a photosensitizer, which accumulates
preferentially in the tumor, followed by its activation with
light. Activation of the photosensitizer induces reactive
oxygen species, mainly singlet oxygen (1O2), that cause cell
death and consequently the regression of the tumor (Juarranz
et al., 2008; Agostinis et al., 2011). Methyl-d-aminolevulinic
acid–PDT (MAL-PDT), a precursor of the photoactive com-
pound protoporphyrin IX (PpIX) intermediary in the synthesis
of heme, is an efficient treatment for NMSC, with resolution
rates ranging from 70 to 90% and superior cosmetic outcomes
compared with other treatment modalities (Fai et al., 2009;
Ortiz-Policarpio and Lui, 2009; Stebbins and Hanke, 2011).
According to current guidelines, topical PDT is effective
for SCC, but, in view of its metastatic potential, topical
PDT cannot currently be recommended for the treatment
of invasive SCC (strength of recommendation D, quality of
evidence ii–iii) (Morton et al., 2008). Nevertheless, there are
some reports of the successful use of MAL-PDT in this tumor in
patients who reject any other treatment either for medical or
personal reasons (Calzavara-Pinton et al., 2008). We have used
MAL-PDT in exceptional patients diagnosed with invasive SCC
and had success in some of them, whereas in others the tumor
continued to progress. In addition, our group has previously
reported that MAL-PDT causes the selection of resistant cells of
a SCC cell line (SCC-13) (Rheinwald and Beckett, 1981) after
several treatment sessions. PDT-resistant cells showed few
differences on intracellular content of the photosensitizer
(PpIX) related to the parental cells, but they presented a more
fibroblastic morphology, higher capacity to close wounds,
more expression of cell–substrate adhesion proteins, and
higher expression of p-survivin (Milla et al., 2011).
On the basis of these clinical and experimental observa-
tions, we have investigated the genomic alterations that might
be implicated in the resistance of SCC to MAL-PDT in patients.
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For that purpose, we have related the lack of response to MAL-
PDT in patients affected with cutaneous SCC and the increase
of the tumor aggressiveness with alterations in the chromoso-
mal pattern of SCC-13 PDT-resistant cells, determined by
comparative genomic hybridization arrays (aCGH).
RESULTS
Patients with SCC treated with MAL-PDT
We have studied six patients diagnosed with invasive cuta-
neous SCC and treated with two sessions of MAL-PDT (cases
1–6, Table 1). In three of them (cases 1–3) the tumor persisted,
recurred, or even metastasized after MAL-PDT (Figure 1;
Supplementary Figure S1 online), whereas in the other three
patients (cases 4–6) the tumor was cured without recurrence
after a follow-up of 24 months. The most striking case was
number 1 because the patient died 5 months after developing
regional lymphatic metastasis and tumoral infiltration of the
parotid gland 4 months after MAL-PDT of SCC on the forehead
(Figure 1). Except for case 3, diagnosed from the beginning
with poorly differentiated SCC, cases 1 and 2 became
histologically less differentiated after MAL-PDT. From a
clinical point of view, there were no obvious differences
between patients with good or bad response to MAL-PDT,
whereas, at the histological level, the most remarkable
difference between both situations was the presence of a
significant inflammatory lymphocytic infiltrate in the tumors
with good response to MAL-PDT, which was absent in those
without response (Supplementary Figure S2 online).
Xenograft tumors induced by PDT-resistant SCC-13 cells
Trying to understand why some human tumors did not
respond to PDT, we used the SCC-13 cells obtained from a
moderately differentiated human SCC (Rheinwald and
Beckett, 1981) and from the PDT-resistant populations (5thG
and 10thG) (Supplementary Figure S3 online) to induce
xenograft tumors in immunodeficient mice. When subcuta-
neous cells were injected into mice, the three cell types
formed progressively growing tumors (Figure 2). Tumors
induced by the 10thG PDT-resistant cells were bigger than
those induced by 5thG PDT-resistant cells, which were in turn
bigger than those caused by the parental cells (Po0.01)
(Figure 2a). In addition, the number of tumors was significantly
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Figure 1. Clinical and histological evolution of a squamous cell carcinoma (SCC) treated with methyl-d-aminolevulinic acid-photodynamic therapy (PDT). The
SCC was located on the left temple of an 88-year-old woman (case 1). Upper panels: clinical SCC at diagnosis (left); the histology shows a moderately
differenciated SCC at low and higher magnifications (middle and right panels, respectively). One month after PDT, the lesion became a poorly differentiated SCC
(middle row panels). Four months later, an indurated tumor appeared on her left preauricular area; the histological diagnosis was parotid gland infiltrated with a
poorly differentiated squamous cell carcinoma (lower panels). Notice infiltrating tumoral nests in the stroma of the parotid gland. Arrows indicate the amplified
areas showed in the panels on the right. Scale bar¼200mm. H&E, hematoxylin and eosin.
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higher in mice injected with resistant cells compared with
those induced by parental cells; 8 of the total 14 injections
with parental cells induced tumors, whereas with 5thG- and
10thG-resistant cells the number of injections that induced
tumors were 9 and 11, respectively. The differences between
the mean number of tumors developed per mouse injected
with the parental and resistant cells were statistically signifi-
cant on days 15 and 30 (P¼0.022 and P¼0.041, respec-
tively) (Figure 2b).
The histological characteristic of tumors induced by par-
ental cells was the presence of mostly well (6/8)- or moder-
ately (2/8) differentiated SCCs that tended to form one cyst per
inoculation, encapsulated in a thin sphere of mouse dermal
connective tissue (Figure 2cA and cA0). Similar results were
obtained with some of the tumors induced by the 5thG PDT-
resistant cells (Figure 2cB and cB0). Occasionally, parental and
5thG PDT-resistant cells induced tumors that grew invasively
beyond the dermis (Figure 2cB and cB0). Conversely, despite
the fact than three of the tumors induced by 10thG PDT-
resistant cells were well differentiated, five of them were
moderately or poorly differentiated SCCs, formed by atypical
keratinocytes with nuclear pleomorphism even infiltrating
skeletal muscle fibers (Figure 2bC and bC0). The immunostain-
ing against involucrin (the antibody only reacts with the
human protein) shows the lower expression of this protein in
infiltrative cells of poorly differentiated tumors than in the
well-differentiated ones (Said et al., 1984; Lan et al., 2013)
(Figure 2cA00, cB00 and cC00).
Evaluation of aCGH of parental and PDT-resistant SCC-13 cell
populations
As the development and progression of SCC is significantly
correlated with the accumulation of genomic alterations, we
next performed an array-based aCGH of the three cell types,
parental, 5thG PDT-resistant, and 10thG PDT-resistant cells,
to determine the potential genomic differences between them.
The SCC-13 cell lines displayed multiple DNA copy-number
alterations. Global results showing the genetic aberration
profiles for all chromosomes are shown in Supplementary
Figure S4 online; Supplementary Tables S1 and S2 online.
Gains were more frequently observed than deletions. The
significant gains were mostly mapped to several broad
chromosomal regions including 1q, 3p, 5p, 7p, 8q, 11p,
12p, 17q, 19q, 20q, and chromosome X. Significant deletions
were observed in 3p, 4q, 5q, 6q, 8p, 9p, 13q, and 21q. As a
first approach, we focused our attention on specific well-
known candidate genes of interest in cancer that mapped at
determined amplified chromosomal regions. In this sense,
all three cell types showed duplication in the cytobands: 7
p22.3p11.2 and 7p11.2 where the EFGR gene is located;
amplification in 11q13.3q13.4 where FGF3, FGF4, and
CCND1 genes are situated; and trisomy in 17p13.1 where
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Figure 2. Xenograft tumors induced by parental, 5thG photodynamic therapy (PDT)-resistant, and 10thG PDT-resistant squamous cell carcinoma (SCC)-13 cells.
(a) Growth curves of the tumors and (b) number of tumors per mouse. (c) Mice at the end of the experiment (upper panels) and histology (hematoxylin and eosin) of
the tumors (medium and lower panels); (A) well-differentiated SCC with infiltrative masses of epithelial cells and horn pearls formation; (A0) detail showing
infiltrative keratinocytes. (B) Moderately differentiated SCC with nests of atypical keratinocytes (arrow); (B0) micrometastases (arrow). (C) Poorly differentiated SCC
with variable masses of atypical keratinocytes infiltrating skeletal muscle fibers (star); (C0) detail from C, keratinocytes with nuclear pleomorphism (star). (A0 0–C0 0)
Immunostaining against involucrin protein to highlight human cells forming the xenograft tumor: inset in (C0 0) showing the low expression of involucrin.
Scale bar¼ 200mm.
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TP53 is located (Table 2; Supplementary Figure S5 online).
However, 5thG- and 10thG PDT-resistant cells presented,
besides these, a distinctive amplicon in 5q11.2 corresponding
to the MAP3K1 gene among others (Table 2; Figure 3a). Main
altered genes also located at the indicated cytobands are
summarized in Supplementary Tables S1 and S2 online.
Potential implication of MAP3K1, EGFR, and cyclin D1 in the
resistance of SCC to PDT
To validate the gains observed in chromosomes 5, 7, and 11
corresponding to the MAP3K1, EGFR, and CCND1 loci and to
interrogate the biological relevance of the functions of these
genes, we next evaluated (i) the corresponding MAP3K1
Table 2. Some genomic amplifications in SCC-13 cells: parental, 5thG PDT-resistant, and 10thG PDT-resistant cells
Alteration Chromosome Cytoband location Start End Size Cell type Genes of interest
Amplification Chr5 5q11.2 56049292 56173104 0,123812 5G, 10G MAP3K1
Duplication Chr7 7p11.2 54412618 56267502 1,854884 P, 5G, 10G EGFR
Duplication Chr7 7p22.3p11.2 92332 57494582 57,40225 P, 5G, 10G EGFR
Amplification Chr11 11q13.3q13.4 68771683 71286976 2,515293 P, 5G, 10G FGF3, FGF4, CCND1
Trisomy Chr17 17p13.1 86809 80993148 80,906339 P, 5G, 10G TP53
Abbreviations: PDT, photodynamic therapy; SCC, squamous cell carcinoma.
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(ERK1/2), EGFR, and cyclin D1 messenger RNA levels in
SCC-13 cells by real-time reverse-transcriptase PCR and the
expression of coded proteins by western blot, and (ii) such
coded proteins in the SCC biopsies obtained from the patients
subjected to PDT by immunohistochemistry. Reverse-tran-
scriptase PCR as well as western blot analysis of the SCC-13
cells (parental and 10thG PDT-resistant cells) support the
results obtained by aCGH; ERK1/2, EGFR, and cyclin D1
messenger RNAs appeared to be induced in 10thG PDT-
resistant cells and also the corresponding proteins showed
strong expression, particularly EGFR and the phosphorylated
active forms of ERK1/2 (Figure 3b and c).
The evaluation of the expression of MAP3K1 (ERK 1/2),
EGFR, and cyclin D1 proteins as well as other markers related
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Figure 4. Immunohistochemical study of squamous cell carcinoma (SCC) with bad response to methyl-d-aminolevulinic acid (MAL)-photodynamic therapy
(PDT). First row shows a well-differentiated SCC before MAL-PDT, second row a moderately differentiated infiltrating SCC after MAL-PDT, and third row the
subcutaneous recurrence as a poorly differentiated SCC (case 2). Cyclin D1 immnunostaining in scattered tumor cells before MAL-PDT (left upper panel) being
more intense and in a higher number of cells after PDT (left middle, left lower panels). EGFR immunodetection demonstrating a positive increasing expression
before PDT (mIddle upper panel) and (middle middle and middle lower panels) after three sessions of MAL-PDT (membranous staining). No signal of p-ERK
was detected before PDT (right upper panel), but after PDT nuclear-positive staining was noted in the least-differentiated cells in the periphery of the tumor
(right middle panel), p-ERK was significantly increased with strong nuclear staining in the majority of tumor cells (right lower panel). The graphs represent the
results of immunohistochemical stains using a semiquantitative method translated into numbers to quantify them: 0 for negative, 1 for mild, 2 for moderate, and 3
for intense in the case of EGFR and cyclin D1, and from 0 to 4 for p-ERK. Scale bar¼ 200mm.
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to the invasive capacity of cutaneous SCC including CD31,
E-cadherin, and KI67 by immunohistochemistry in the patient
biopsies is shown in Table 1; Figure 4. In the cases without
response to PDT, we observed increased EGFR expression,
except for case 1 who showed maximal expression already
before the treatment (Supplementary Figure S6 online). A
similar expression pattern was observed for cyclin D1,
although to a lesser extent. KI67 and P53 did not show any
consistency. In addition, the expression of p-ERK significantly
increased after MAL-PDT in nonrespondent patients (Table 1);
(Figure 4). Related to the cases with good response, the most
remarkable finding was little or non-expression of EGFR and
cyclin D1 in the tumors before the treatment (Table 1). All
these results obtained either in the SCC-13 cultures or in
patient biopsies indicate a role of MAP3K1, EGFR, and
CCND1 genes in the resistance to PDT.
DISCUSSION
MAL-PDT is one of the most effective treatments for NMSC.
However, some relapses do occur. In this work, we have used
patient samples and MAL-PDT-sensitive and MAL-PDT-resis-
tant cells to analyze the genomic changes that may mediate
the acquisition of refractoriness to MAL-PDT in SCC, and have
focused on a handful of genes that crucially control tumor cell
proliferation. SCC-13 cells resistant to MAL-PDT (5th and 10th
PDT-resistant generations) (Milla et al., 2011) presented a
higher tumorigenic effect in immunodeficient mice than their
parental cells and proved that genomic imbalances and
overexpression of CCND1, EFGR, and MAP3K1 are involved
in the development of clinical SCC resistance to PDT.
Only few studies have focused on recurrences and the
aggressiveness of nonrespondent skin tumors to PDT. With
respect to basal cell carcinoma, it has been described that
post-PDT recurrences appear to display an increased histolo-
gical aggressiveness (Fiechter et al., 2012). Concerning SCC,
the degree of cellular atypia has been proposed as a negative
prognostic factor, suggesting that poorly differentiated
keratinocytes are less susceptible to PDT (Calzavara-Pinton
et al., 2008). In our study, we have not found that the grade of
differentiation of the SCC influenced the response to MAL-
PDT. The only distinctive histological factor was the presence
of an intense inflammatory lymphocytic infiltrate in the
respondent tumors. Although this infiltrate is a prognostic
factor in some tumors, such as melanoma, its significance in
SCC is not clear (Azimi et al., 2012). However, its presence
could be considered as a host antitumoral response, which
could contribute or even increase PDT effect (Talmadge,
2011).
Our data using aCGH clearly revealed the existence of
chromosomal instability in SCC cells, both parental and those
resistant to PDT. On applying aCGH, consistent amplification
of the chromosomal region 11q13, which is associated with
CCND1, has been detected in different stages of SCCs (Utikal
et al., 2005). Overexpression and genetic aberrations of EGFR
have also been described in metastatic cutaneous SCCs
(Shimizu et al., 2001).
Cyclin D1 overexpression is frequently involved in kerati-
nocyte carcinogenesis and it is an early event in cancer
promotion (Alao, 2007; Jensen et al., 2010). Our previous
reports indicate that PDT reduces the expression of cyclin D1,
KI67, and P53 in actinic keratosis (Bagazgoitia et al., 2011).
However, according to the present study, all the respondent
patients were negative for cyclin D1, whereas the nonres-
pondents were positive and their expression increased after
MAL-PDT. Therefore, cyclin D1 could be a differential marker
between respondent and nonrespondent SCCs to MAL-PDT.
The EGFR pathway is very important in the therapeutic
efficacy of PDT against cancer (Martinez-Carpio and Trelles,
2010). Array CGH revealed amplification of the chromosomal
region 7p11.2, which leads to EGFR overexpression in
primary and recurrent SCCs after MAL-PDT, although the
reactivity patterns of such lesions were different. The primary
tumors were weakly and focally positive, whereas the recur-
rences were diffusely and strongly positive. High expression of
EGFR protein has been correlated with aggressiveness, poor
prognosis, short survival, and development of resistance to
cytotoxic agents in some tumors (Brabender et al., 2001),
including cutaneous SCCs (Shimizu et al., 2001; Ch’ng et al.,
2008). Immunohistochemical analysis of our patients sug-
gested that higher expression of EGFR before MAL-PDT could
determine a bad response or may even increase the metastatic
potential of the tumor. Furthermore, in cases of low expres-
sion, MAL-PDT could increase EGFR expression. Our results
are consistent with those reported by Edmonds et al. (2012)
who found that PDT stimulated EGFR phosphorylation and
nuclear translocation, whereas the inhibition of EGFR signal-
ing led to an increase of PDT cytotoxicity. Conversely, PDT
has been shown to reduce the expression of EGFR in tumors
induced by UVB in hairless mice (Ahmad et al., 2001) and,
within the time period of the reaction to PDT, normal and
malignant cells lose their responsiveness to EGF and some
cytokines (Martinez-Carpio and Trelles, 2010). The role of
EGFR in the refractory response to PDT has been highlighted
by the combination of PDT and EGFR inhibitors to act syner-
gistically (Bhuvaneswari et al., 2011; Postiglione et al., 2013).
In addition, our results indicate that the mitogen-activated
protein kinase MAP3K1 is increased in MAL-PDT-resistant
5thG and 10thG cells. The mitogen-activated protein kinase
family drives cell proliferation, differentiation, and survival
processes in different cell types. One of the mitogen-activated
protein kinase-signaling cascades involved in most relevant
human cancers is mediated by the phosphorylation of ERK1/2
(Roskoski, 2012). The elevated expression of p-ERK observed
in SCCs in this study is consistent with high levels of the p-ERK
frequently correlated with tumor aggressiveness and higher
proliferative activity (Zhang et al., 2007). In this sense, it has
been described that sustained ERK1/2 activation protected
cells from PDT (Tong et al., 2002) and a recent study using
A-431 epidermoid skin carcinoma and WiDr colorectal
adenocarcinoma cells linked EGFR and ERK activation as a
potential predictive factor for response to PDT (Weyergang
et al., 2013).
Our study raises the possibility that PDT favors the selection
of more aggressive tumor cells and, taken together, these
results indicate that the MAPK/ERK signal pathway may be
an important potential factor in the resistance to PDT. The
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activation of EGFR leads to sustained activation of ERK,
activating the overexpression of cyclin D1, among other
effects, and these signaling elements may counter the bene-
ficial effect of PDT. Previous studies have demonstrated that
MAL-PDT induces the production of reactive oxygen species,
a key factor for the destruction of target cells; however, if
some SCC cells received sublethal doses, it could promote a
moderate production of endogenous reactive oxygen
species, which efficiently stimulates cell growth, as it has
been proven in human immortalized keratinocytes (HaCaT)
(Blazquez-Castro et al., 2012).
One of the limitations of our study is the size of the sample
with only six patients. However, it has to be considered that
MAL-PDT does not have an approved indication for invasive
SCCs, therefore it is only exceptionally used. Another limita-
tion is that we did not quantify the fluorescence of the PpIX
accumulated in the tumor, therefore we cannot rule out that
an insufficient conversion of MAL to PpIX could have
contributed to the lack of response. However, this would
not explain the change in tumor cells’ aggressiveness.
In conclusion, our findings provide a better knowledge of
the resistant mechanisms of SCCs to MAL-PDT and may
contribute to well-informed patient selection when physicians
are contemplating the use of PDT for SCCs. As aggressive
cutaneous SCC can compromise the life of a patient, the
results of our translational investigation support current clin-
ical guidelines that recommend great caution when using PDT
for invasive SCCs.
MATERIALS AND METHODS
Photosensitizers
For PDT in patients, a methyl derivative of MAL in cream (Metvix,
Galderma, Lausanne, Switzerland) was used. For phototreatment of
cell lines, MAL (Sigma-Aldrich, St Louis, MO) was prepared at a
concentration of 10 mM in deionized sterile water. Appropriated
dilutions were prepared in DMEM culture medium without serum.
Light sources
Patients were exposed to a monochromatic light source with a multi-
light-emitting diode system (coherent light) 636 nm (Aktilite). For cell
irradiation, a multi-light-emitting diode system (WP7143 SURC/E
Kingsbright, City of Industry, Los Angeles, CA) of 635±17 nm and an
irradiation intensity of 6.2 mW cm 2 (as measured by Coherent Laser-
Mate Power Meter, Merchantek, San Diego, CA) was used.
Antibodies
The antibodies used were as follows: anti-rabbit polyclonal antibodies
against ERK 1/2, p-ERK ½, AKT, p-AKT, FGF4, FGF8, cyclin D1,
EGFR, KI67, anti-mouse monoclonal antibodies against E-cadherin,
b-actin, Involucrin, P53, horseradish peroxidase mAb anti-IgG of
mouse, and horseradish peroxidase mAb anti-IgG of rabbit (Supple-
mentary Table S3 online).
RNA extraction and reverse-transcriptase PCR
Total RNA was extracted and purified with the RNAeasy Mini
Kit (Qiagen, Hilden, Germany). RNA from each sample was retro-
transcribed to complementary DNA by the use of the ‘‘High capacity
RNA to cDNA kit’’ (Applied Biosystems, Foster City, CA).
Complementary DNA samples were used as templates for amplifica-
tion reactions carried out with the LC480 SYBR Green I master
(Roche Applied Science, Barcelona, Spain) following the manufac-
turer’s instructions. Data from PCR amplifications were analyzed with
LightCycler 480 software 1.5 (Roche Applied Science). Duplicate
determinations were made, and the gene expression was determined
by the DDCt method using the probe Hs99999901_s1 18s rRNA as a
reference gene. The primers used in this study were for human EGFR
forward primer: 50-TTTGCTGATTCAGGCTTGG-30; reverse primer:
50-AGAAAACTGACCATGTTGCTTG-30 (Toby et al., 2010) for human
cyclin D1 forward: 50-CCGTCCATGCGGAAGATC-30; reverse 50-GA
AGACCTCCTCCTCGCACT-30 (Medeiros et al., 2002), for ERK1/2.
forward: 50-CCATTGGGTTGTGGAGGCAATG-30, reverse: 50-CACTC
TGGGGATCAGTAAGGAC-30 (Wang et al., 2011).
Patients
Patients diagnosed with invasive cutaneous SCCs and treated with off-
label MAL-PDT, because standard treatment options had been
medically not recommended as first-line therapy, were included in
the study. They were treated from January 2007 to December 2009 at
the Dermatology Unit of Hospital San Jorge (Spain). Epidemiological,
clinical, and histological data were collected (Table 1). Patients were
subjected to PDT according to the approved procedure: curetting or
debulking of the tumors, application of 160 mg g 1 MAL cream
(Metvix) for 3 hours under occlusion and illumination with Aktilite
(37 J cm 2). PpIX fluorescence was routinely confirmed before
irradiation and its disappearance after it.
Cell types
The cell line used was the SCC-13, obtained from a moderate SCC
located on the face (Rheinwald and Beckett, 1981). Cells resistant to
PDT were obtained as previously described (Milla et al., 2011) by
exposing the SCC-13 cells (parental) to several cycles of PDT (1 mM
MAL, 4 hours of incubation and variable light doses of red light: 3.75,
5.5, 7.5, 11,5 J cm 2). The final population received a total of 10
cycles of PDT (from 1st to the 10th resistant generation). Their
resistance abilities were checked by the (3-[4,5-dimethylthiazol-2-yl]
-2,5-diphenyltetrazoliumbromide) assay (Supplementary Figure S3
online). Cells were cultured under standard conditions in complete
medium DMEM and antibiotics (Gibco Invitrogen, Carlsbad, CA).
Tumorigenicity assays of SCC-13 cells in nude mice
The in vivo tumorigenicity of cells was assessed in 2–3-month-old
hairless athymic nude mice (AthymicNude-Foxn1nu, Harlan, Barce-
lona, Spain). The same number of cells in each case, parental, 5thG,
and 10thG (10 106 cells in 0.3 ml of phosphate-buffered saline), was
subcutaneously injected in each flank (right and left). The size of the
tumors, blindly monitored weekly by the same investigator over 35
days, was calculated from calliper measurements of two ortogonal
diameters. Seven mice were used for each SCC cell type. Mice were
killed 35 days after administration of injections and tumors were fixed
in neutral buffered formalin, sectioned in paraffin, and stained with
hematoxylin and eosin or subjected to immunohistochemistry.
CGH array
For chromosomal aCGH, DNA of SCC-13 cells (parental, 5thG PDT-
resistant and 10thG PDT-resistant generations) were isolated from
exponential cultures using the Qiagen DNEasy Kit. Whole-genome
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analysis of the cells was conducted using a commercial 60-k
oligonucleotide human array-CGH (AMADID 21924, Agilent Technol-
ogies, Santa Clara, CA) following the manufacturer’s protocol (Barrett
et al., 2004). Healthy female DNA (Promega Biotech, Madison, WI)
was used as hybridization control. Microarray data were extracted
and visualized using Feature Extraction software, v10.7 and Agilent
Genomic Workbench, v5.0 (Agilent Technologies). Copy-number-
altered regions were detected using ADM-2 (set as 6) statistic pro-
vided by DNA Analytics, with a minimum number of five consecutive
probes. Microarray raw data tables have been deposited in the Gene
Expression Omnibus under the accession number GSE50602.
Western blots
For western blot, cells were lysed in radioimmunoprecipitation assay
buffer (150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS,
10 mM Tris-HCl pH 7.2, 5mM EDTA, Phosphatase Cocktail, and
Protease Inhibitor Cocktail) (Sigma-Aldrich). Protein concentrations
were measured using the BCA Protein Assay Kit (Thermo Scientific
Pierce, Rockford, IL). The proteins were electrophoresed, blotted on
Immobilon-P PVDF membranes (Millipore, Billerica, MA), and incu-
bated with the first antibody overnight at 4 1C. Afterward, membranes
were subjected to the peroxidase–conjugated secondary antibody and
developed by chemiluminescence (ECL, Amersham Pharmacia Bio-
tech, Little Chalfont, UK) using the high-definition system ChemiDoc
XRSþ (Bio-Rad, Hercules, CA). The bands corresponding to the
proteins were digitalized using the Image Lab, version 3.0.1 (Bio-Rad
Laboratories), Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA),
and Image J 1.44 (National Institutes of Health, Bethesda, MD).
Immunohistochemistry
Sections of human and mice skin biopsies were subjected to
automated immunostaining (TechMate 500, BioTech Solutions, Dako,
Glostrup, Denmark) and then incubated in a detection kit (Chemate,
code K4001, Dako) according to the manufacturer’s instructions.
Color was developed by 3-amino-9-ethylcarbazole solution as chro-
mogen (Dako). Heat-induced epitope retrieval was performed using a
pressure cooker. Representative sections were examined using
positive and negative controls. The antibodies used are in the
Supplementary Table S1 online. Evaluation of immunohistochemical
staining was performed by counting the number of cells with a grid
that expressed the antigen studied, in 10 high-magnification repre-
sentative fields. The percentage of positive cells was established for
P53 and KI67, whereas a semiquantitative method was used for EGFR
and cyclin D1 (0p10% of the tumor cells staining; mild¼ light
(intensity) and incomplete (quality) staining in 410%; moderate¼
moderate and complete staining of 410%; and intense¼ intense and
complete staining 410%) (Sweeny et al., 2012) and p-ERK: grade
1:o5%; grade 2: 5–25%; grade 3: 26–50%; and grade 4:450% of
positive cells (Zhang et al., 2007). To represent the results graphically,
the semiquantitave staining measures were translated into numbers: 0
for negative, 1 for mild, 2 for moderate, and 3 for intense in the case
of EGFR and cyclin D1, and from 0 to 4 for p-ERK. To avoid
interobserver variability, the same pathologist evaluated all samples
and he was blind for the clinical data of the patients.
Microscopy and statistical treatments
Microscopic observations were made with a microscope Olympus
BX61 (Olympus, Center Valley, PA) with a CCD digital camera DP50
and processed using the Adobe PhotoShop CS5 Extended, version
12.0 (Adobe Systems).
The values in the figures and tables are expressed as mean and SE.
Comparisons among the means of the number and size of induced
tumors in mice as well as among the means of the (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide) assay were
made using analysis of variance test for those variables with normal
distribution and the Kruskal–Wallis tests for those deviating from
them. The threshold for statistical significance was set at Po0.05.
Analysis was performed using the STATA software (STATA, Version
7.0, StataCorp, College Station, TX).
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